TNF Receptor and TNF Antibodies
TNF receptor-targeted therapies are at the forefront of treatments for oncology and autoimmune diseases, including arthritis and inflammatory bowel disease (IBD). Modulating TNF receptors is crucial in these treatments, using the dual approach of antagonistic and agonistic antibodies to fine-tune immune responses. No matter which disease you delve into, the antibodies you choose serve as your most crucial tool. They help you achieve clearer insights and more conclusive results.
Agonistic and Antagonistic
Hycult Biotech has made a precise selection of antibodies that target TNF receptors and TNF-alpha. These antibodies play a dual role as essential biomarkers and functional active reagents, providing crucial insights into the complex inflammatory cascade of the TNF signalling pathway. Antagonistic antibodies to TNF receptors play a key role in reducing inflammation and autoimmune responses. On the flip side, agonistic antibodies enhance the efficacy of TNF receptors. As an example, the widely used MR2-1 antibody has shown to be a valuable tool for modulation of regulatory T Cell (Treg) activity. Find the right antibody for your research in the selection below:
| Antibody Name | Applications | Characteristics/notes | Article Number |
|---|---|---|---|
| TNF-RI | |||
| TNF-RI, Mouse, mAb HM104 | FC, F, IA, IP | HM1009 | |
| TNF-RI, Mouse, mAb 55R-170 | FC, FS | Antagnostic antibody useful for blocking of TNR-RI both in vitro and in vivo | HM1097 |
| TNF-RI, Mouse, pAb | FC, FS, IA, IP, WB | HP8002 | |
| TNF-RI, Human, mAb MR1-2 | FC, FS | HM2005 | |
| TNF-RI, Human, mAb H398 | FC, F, FS, IA, IP, WB | HM2020 | |
| TNF-RII | |||
| TNF-RII, Mouse, mAb HM102 | FC, FS | Agonistic | HM1011 |
| TNF-RII, Human, mAb MR2-1 | FC, FS | Agonistic antibody and receptor modulating antibody, useful for cell (culture) experiments | HM2007 |
| TNF-RII, Human, mAb 80M2 | FC, FS | Functions as an allosteric modulator, which stabilizes the ligand-receptor complex | HM2022 |
| TNF-RII, Mouse, pAb | FC, FS, IA, IP, WB | HP8003 | |
| TNF-RII, Human, pAb | FC, FS, IA, IP, WB | HP9003 | |
| TNF-alpha | |||
| TNF-alpha, Mouse, mAb V1q | FC, FS | Neutralizing antibody | HM1021 |
| TNF-alpha, Human, mAb 4H31 | FC, FS, F, IA, IP, WB | Useful for inhibition of the biological activity of TNF-alpha | HM2009 |
| TNF-alpha, Human, mAb 52B83 | FC, F, IA, WB | HM2010 | |
| TNF-alpha, Human, mAb T1 | FC, FS, IA, WB | Useful for inhibition of the biological activity of TNF-alpha | HM2024 |
| TNF-alpha, Human, mAb T3 | FC, FS, IA, IP, WB | Useful for inhibition of the biological activity of TNF-alpha | HM2026 |
| TNF-alpha, Human, mAb 5N | FS, IA | Useful for inhibition of the biological activity of TNF-alpha | HM2218 |
| TNF-alpha, Mouse, pAb | FC, F, FS, IA, P, WB | HP8001 | |
| TNF-alpha, Human, pAb | FC, FS, IA, WB | HP9001 |
Our services
We understand the value of good antibody production. Antibodies are key in company processes and even commercial operations. The production of your antibodies should therefore be something which you should not have to worry about. Use our knowledge to develop your next product. Find out more about the services of our sister company Biocult and get customized support tailored to your needs.
Latest Hycult Biotech news
- New ELISA for Human C3 Nephritic Factor (C3NeF)
We are pleased to introduce our new ELISA kit for the detection of human C3 nephritic factor (C3NeF), a key autoantibody involved in dysregulation of the alternative complement pathway. Key features Why measure C3NeF? C3 nephritic factor (C3NeF) is an autoantibody that binds to and stabilizes the alternative pathway C3 convertase (C3bBb). By preventing normal… Read more: New ELISA for Human C3 Nephritic Factor (C3NeF) - New Healthcare Project: Improving kidney disease care through standardized immune blood testsWe are excited to announce our participation in the new COMPASS project, funded by Health Holland. COMPASS brings together two academic medical centers and Hycult Biotech in a public-private partnership to develop reliable and standardized immunoassays that enable earlier detection of kidney diseases earlier and more effective monitoring of treatment responses. Kidney diseases caused by… Read more: New Healthcare Project: Improving kidney disease care through standardized immune blood tests
- Important Company Update
Expanding Biocult Services Biocult Expands Services with new Team and Technology UDEN, Netherlands, March 30, 2026 Biocult, part of Hycult Biotechnology B.V., has expanded its organization with new scientific expertise, additional technological capacity, and a strengthened development team. With this strategic expansion, Biocult now offers assay development services alongside its established manufacturing services, providing a… Read more: Important Company Update
